HUE028954T2 - Heterociklusos vegyületek és alkalmazásuk - Google Patents

Heterociklusos vegyületek és alkalmazásuk Download PDF

Info

Publication number
HUE028954T2
HUE028954T2 HUE08727163A HUE08727163A HUE028954T2 HU E028954 T2 HUE028954 T2 HU E028954T2 HU E08727163 A HUE08727163 A HU E08727163A HU E08727163 A HUE08727163 A HU E08727163A HU E028954 T2 HUE028954 T2 HU E028954T2
Authority
HU
Hungary
Prior art keywords
mmol
nrara
chloro
mixture
alkyl
Prior art date
Application number
HUE08727163A
Other languages
English (en)
Inventor
Yi Chen
Timothy D Cushing
Jason A Duquette
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Xiao He
Brian Lucas
Lawrence R Mcgee
Andreas Reichelt
Robert M Rzasa
Jennifer Seganish
Youngsook Shin
Dawei Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HUE028954T2 publication Critical patent/HUE028954T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (5)

  1. HEi^Kociiassos vegyöleter is âijkalmazAsus: lëabaàÂti %éæyps3stbk 1, Á:k8yfeíkex§ :SKsrks2eís %iáiSÍ«ííÍ vëgyfe::
    vagy hàrë^y.gyôgyàmft%g'©îfesgÂaté mÿi, akd ,X: jelzésé 00^ X; jdentésebí' V jelentéseN(R!l},()vagyS; Z MeÄeCES-agyN:; &amp; értéke 0. %, 2 mg y 3; S! jebatése közvetlen kíáessel vagy ^sg^«^«fe^í-^s!Sö|ó# tÄst, resafeea-fölítea vagy tetíRtkax Ss '&amp;· vagy /-tagú. N, O vagy S kézül választott ö,. 1, 2, 3 vagy 4 atomot taiíaítnasó, dg egynél több O vagy S gtomaknom tartalmazó msjoocik&amp;i«? akti a §y#rü Eqzsiprbéíö széttâtottïiai 0, 1 vagy 2 φχο vagy ioxo csoporttal szabsztít»altak. aWagyíírú 0 vagy l R? saxbs^tteRaseí sstobsztitnáít. és a gyűrű tovább sssabsztitnák % 1, 2 vagy 3 ssobsztónopásd, aiKeîî^k'.«^àsÈÂ'%^fe^i' a kővetkezők kézül választottak: bab, intro, oiano, C^albt, OCs.^«, OC^hsbdkii, és q^kaloaÄ R2 jelentése bab, G.Jukxdkíl ciaao, nitro. -CÍ~0}R<!, -a<>)OR\ -QK>)NR*R*, -Ct-lsR^N^R3, -OR*, -ocb-o)R\ -ocqopÄ -oe^MW$í*:0^ ~SRS, -s<*o)R*, -S(<>)2r, -SbCOxN^R'', •${-0}jN(R;,}C(K)}Rt>: ·ΚΕ;Έ;', ••NíR^K:;{<).íOR\ -ΗίΕ^ό^Ρ^» -NÍR’jC^T'^NR'R*, -NíR*)S{K>hR8s «^slk|er és ÄC^aiyiö^köaäl válasrtc·«; vagy Ra jelentése C,*a!ldl, lepik tesal, teroarsi teroelklos, -^jalkil^ewpasl ^CMÄi)hetaöÄ$, -<3(e|.:3Äii}haioroadi,; aíCi.yiMl^etertícikte -Mqet,jatkil}batomartk Ä|Ct.;;aM13bobtxtciksos, ,(Ç.paMpi«i, -ÖiC,.#;-és -ME3CC:.3áM|&amp;si MbM választott, arndyek «iaé^tfee 0, 1, 2 vagy I szebszíttitcfissel srabsznatsH, antety Cí .«hsloalkik OCiaslkik Br, Cl, P, Î és C:.4aikít közül választott; R3 jelentése H, hé* Ct4MmMl attno, nitro, -CH»R*, -CK>)GR\ -C<-0)M<sRs, -C{»NR*)NR*R*, -OR*, -OCó- 0)R\ -0C(«0)NR*R*, -0€{-0}Ν(Β8)$(=<);·:»Ε;). -OC^Uk0MRÄRÄ, -OC^alRilOR3, -Síi5, -S(0)R* -S(==0),R3, ~SbO}5RR*R\ -S(-Ô3>N{R5)C(-0)RX -S{-0)iN(B.a}C(-0)HRsRs, ÄSR\ -N(R*)C{*0)R*, PirjGHïpE5, -N(RstC(»t.)pRsR5, -ifiP« -N{R*)$H>)jR\ -NtROSC-öi-NR^R3, «IJIÄBn -RR^^itiMiOR3 C;.^!kii, tont!, benztk heteroarik és heterodk- lus közül vámmii, ám » C^lfeR, toMvUtteni# és feetenscifelus tovább szübsztlmált % 3,, 2 3 szubsztituenssel, amely C) .ploslkíl, OC-^aikik Br, Cl, F, 3 cs C^-sikH közöl választót;; R4 jeiontése nimden esetben, egymástól föggetletmL bak;, nitro, eiano, €(..ριΜ1, OCt.$a!kií, ÖC^baioalkil, N'HC')...ia;kjl, N(C;.4aikil)C:,4alktl vagy Ci.pdoalkil; Is jelentése miacfeu essifcesï,; egymástól függetlenül, B, Si; Ci,sÄk €},patoaI3al, vagy Ci^aMl 1, 2 vagy 3 sxubszístoeassol szifesztkuák. amely hale, e;ar,o, OH, OC'i^alkk, CPalkii, Ctohaloalkil, OCj ^alkiS, NH2, Ni;C;.,:alkiL ííP^álktpG^M közöl válássá*««; vagy mindkét RÍ csoport együtt C^sptroaikii csoportot alkot, amely ü, 1, 2 vagy 3· szubszdtuenssel .^abssáeA graety sgabs^ltuoíts tío, dano, OH., OCMaik!k Cj 4alMl, O, oíMoalktl, fX^ksí, WCt ^ÄfÄÄil vMaszfelt; R8 jsleaiése H, halo, 0;i,salki, Cf^haloatkik ciano, nkro, -C{“-'Ö)R\ -k;{ '0)0R\ *C('::0)Nk''Re, C(:-N.R‘> KR8R:\ -S(--Ö)R\ -S{= 0}>RS, -S(-€%NR.8R8, -S(«Oj,N(Ral€0-0)R:i, -StpO^CR^e^OlOR8, -S(-Ô)>N-(RíjCÍ-OlkíR^R* közöl választott; Rí jeleotése M, haló, C(,galkti £f .«haindkii, ®iano, nitro, .Ç{“R)}R8 4d^ö)(lR'·, X(~NRÍ)-· NR8R8, -Sfe€>)E\ ~S(-0}>Rs, -%0}sNÄ ~$ί~0)2Π- (Rs)C;-05BRaRs közRl vákisztoít; Is jblemése !!:, pjtsioalkíl,:B*,Cl, F, 3, ÖR* BR*R*.:C^sMî» IstÄ berni, heteroarlésbeterooíklas közül választott, ahol &amp; C^&amp;lMh Jeni,. bemal, heteroazíl ;ós heteroctkáus tovább szabsztitaált Ö, .1,2 vagy 3 szs^. szíjtucnssd, amely Cj.jhaloaifcii, Bt, CL F, 1 és iCj^alkti közül választott; R® }de»tése H, haló, C;..:haioalkil, cisno, nitro, ·€ό::0)Κ3, -€(=-Ö)OR8XpO)NR3R3, -GÍ-MR^MSÍSÍ, -ÖR", -0C(-'Oííi8, -OCPÖ)NR*R\ -OCC-OlNCriSC-OkR8, -OC^aik'iiÄ* -OC^aíídlOR8, ·«* -SpÖ)!3, -8{-0};;Rs: -8{-Οί>ΝΠ:\ - 8Ρ0);Ν(|13)0(“0}Κ*, -SpOhNCRlÇ^jOR8, -NR8R8,: wM(R*)C(-0)R*. -N(Rä)C(-OlORa, -Nt R")< ’{«Ö)NR*R* PlfR*)€pBR*)NÄ*,. -:B(Is)S:(^0);NRsRa, -BRsCMalkilNR*R*, -NR'O.„alküOR5. Csalid;, fen!;, benzd, fétefeadl és Moro-oikkäs: közöl vál&amp;szíött, ahol a Cj^alkií, -fesltí, henal, hetesxTaril és hetetocikios -tovább szufesztshi&amp;b 0. 1, 2 vagy 3 sanbSgti&amp;eísssol, aáfely haló, Ci.^fcűoaifeil, etano, nitro, -€<=“0)R*, -C(--O)OR!l, Ό “OlNR^Rk C("=NRS)N'RÄR8 >OBÍ, *Ú€F pÖ}R*, -OC(~ö)NRaRa, -OCeOlNtR^iSe-O)^, -OC^alkilNRaRa, -C.X;, .aîkilOR*, -SR*, :*5(«0}R% -•Sí-OgR5, -‘Sí-OjNR^ -S^feNÍR^CHlip15,, -St-OhNtR^a^OpRÍ -S(^N(R^|*<>)NR*K*.· -NR*Re. -NíR3)C(K:0)Ra, ^(I^ef-OIORÍ, -N^í.^-0}NRaRa< -N(R*)C(“NR*)NR*R*, -N(R*)S(-0)2BR*R* -NRAe2,mMORs közöl választott; vagy Rs jelentése tellett, feszbeo íglRett víígy Mhetlet; 5», 6* vagy 7'tagó, M, 0 vagy S közül ydassttotk 1, i, 2., 3 yagÿ 4: &amp;toínot:tartabuazó toottosÉlosos gyűrő, de öem tartaímaz egynél toll Ö vagy 8 atotttoí,: aboí a gyqrü hozzáfethetö szeoatottgai ö, 1; vagy 2 oxo vagy tiaxo csoporttal: szabsztltuáltak, altoía gyürü B,, 3,2,3 Vi^: 4 .S23tis2toáiU fedte, C irkálóé Ildi, ciaao, ttitro, -C(-0)R*, -0(^0)0¾ 'Ct'-OpRlRí, PH4RS}B«, -ÖR8, -OGpÖjR^ -ÖÍ^ÖjNRP*, -OayOp(RnS( <0jRö -«atliÄ <QGmah RtlOR8, -SR8, -S(~Ö)R3, PpO)p?J: -SH1NÄ -SCKljPCRnCC-OlR8, -SH<))P(R8)C(-O)0R:i: PH>)ÄH3)CO<))lN®CR8: prR3, .MV; -MpOCHBOR8, -NfR8)- C(=-NR3)BRSRS, --BtiriSpQiprR8, -'NR3Cj.yükllN:R8R8 és -NR3Q>.öalkilOR3 közül vá lasztott; R! ! jefeatése M vagy C^alkil; Ra jdesíése mirKiea esePsea, egymástól ifeggetlessöl, 11 vagy Rb; és IIs jdestese m&amp;úm «sæfee», egymástól taggedesäl, ímö, beazil vagy Cj^alkii, a IPetl, berrnil és Cj^alkü 0. 1, 2 vagy 3 ssabszíáae®«) sxataftaáK. lefed, és a ss'efesdifeseas halo, -CjuAílj Cs.jb&amp;baMI» ΌΟί,.^ΙΙίϋ, 'MH;;, ^KCmsSî», ·Μ<€í,4aBíií}€:í.«aikP kézál választolt 2, ,4z Ϊ. Igétypoat szentfei kö vetkézé szerkezeti képteíü vegyülsl;
  2. 3. Az L Sgenypoßt szerinti, következő szerkezeti kép-tető vegyetek-
  3. 4. Az Î, tgéííypöMszeíisti következő szetiesett képiető vegyőtef:
  4. 5, M L igénypont szednss ve-gyölet, afeoli R! jelentése F, Cl vagy Sr; és a értéke 0. &amp;M i. igénypont SKemti yegyßtet, ahoi R! jelentése 0 vagy Í ïi! szubsruitueassdsmMzätoMtfeniks* a feni Ci, I, 2 vagy 3 s^fcsatíteesssel tovább halo» nitro, ciano, €;. ^alkil, €€:.4&amp;ΓκΙ1, OC^iMalklÄCiÄ, NÎC:; .4si:kii>C.;.4aIksJ: és CMhstoafkM fösüi Mksxto&amp;
  5. 7, Az L %éftÿge8t vrerMt vegyik*, ahokR1 jekstése kärveüea Mfesset vagy okígánea ksrmzí&amp;l kaja ösoíoiib tóiietb réxaben-tfôiîvfVvagy teliteken >.. 6- vagy 7-tagä, N', D vagy S közül választott, i, 2,3 vagy 4 sttnset ísnateszái». de egysei s§bb 0 vagyis atontot nen; iastaltnazó rsgiissaiMöses gyitrik iW a gysM tmsfek kékésre álló szénatomjai 0, I vagy 3 am vagy iloxo essforUal sxabsKtifeÄk, fel a gyikf § vagy l io SKsbsziibíbösSd SíbbsKtiíuált, ás a gytrü tovább »ánbsatiátáli ë.,·. 1, 2: vagy 3 sanbsxktaénsseij aníejy egÿniasîôt feggíklenül a kbvstk&amp;Ä lbzä! válásaiéit: halo,. nitre, tism, C^sSM, ÖQ4ÄM, MCi4â}ki)C<.#ïkil «s CiJbdo&amp;Mi'y g. As: 1. igénypont szerinti, kővetkező szerkezek képiéül vegyüist
    vagy a> b) ás <?) bánts«!yíká»ek Mrœdy gybgyászatilsg slfögü$»® sfeä· 9 Ag ;gányx»i5t sserinö vegyük* szabad bázis femfejsban' 'ϋϊι Aa 1*9. igénypontok. feánaelyike szAKki vegyűietet és gyágydszablag: «IpgMbató Éigííésszert vagy hordozói tartaknaxó gyógyászati készítmény. II , Az ÏA. igetîypsbôk bfeielyiké szeséái vegyül# rhemaisldid artîihssî, spoiixMiiis aækylapiæM** osieoarbitm, p^oáékm |>S2&amp;#Ä gyulladásos betegségek és sstósa»* ^betegségeik, gyulladási bélb«®gseg«^ gyulfeddsos î«!Ç8Âi«s^» gyulladásos vagy tefc8>$ l^ylélyág-íesdsIfertöSsegek, bár panaszok gy#laáásos elemekkel kÄkus gyulladásos MI#xáok, autoimrnuö betegségek, ssisziémás îyji órylhfiOiáfesós ISLE):, myaatííesia grakts,: yeyb?aiotd aidrítisz, akut disszidált ebcspkateisyslitis, Mopá&amp;ás troïisbo(Ok>jïeb||$ p«â|îarif, sskteréiss: multiplex, Stógiési-sziudréíua és aetoimmüb IäoIÄss süéttiía, allergiás állapotok# tűlébAkeííység keMésám idrl#» alkslraazásfá, II, Az W. }0iÿpœêï!k bármelyike szeripi vegyuleí p l 10§ aMvI^ssalMzvgfkg«, apái iiggŐ vágy ab-hoz kapcsolódé Ä'Äsi^s%i?attoaS.ais:^masÄ^> Í3. M 1-9. igéaypffiíííok bámtelyifce szermis vegyulet vaslagbélrák, glioi#s#áma, vziáomeiééHs Mm-:#53ga, bsgaíseetolám fék, ííklórák, msktftóssta, vesese|í-ksrdsófSa, palxstmrjgy-kiim, imíöma, iimfopro·· ']%$mÉ$·. w^élíesess^elj Ötsejtss tüdSrék, pikkelyes sejtes ISdirák, gbbi^gj epíískak, prosx!»tik, peíe%^k·· yâk. pébayakrák, leukémia, akatdiékíM |öiké»kas myelödysplpiás sgmdrdtsrav sfildopmliletstik ttiegbetegedé-sífkj krónikus myelolá: leukémia, Τ#ρ|ί«&amp; akiit )te|pblssxk>s leakémia, B- sejtes stet bmíobIaá#ós leukémia, oesxvHodgkm lipîiiSi&amp;a, B-seiliesÄÄ^didÄPä '^atpr#;:k««»í^élTO történd .alkalmsaim
HUE08727163A 2007-03-23 2008-03-24 Heterociklusos vegyületek és alkalmazásuk HUE028954T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91956807P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
HUE028954T2 true HUE028954T2 (hu) 2017-01-30

Family

ID=39645618

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08727163A HUE028954T2 (hu) 2007-03-23 2008-03-24 Heterociklusos vegyületek és alkalmazásuk

Country Status (24)

Country Link
US (6) US8193199B2 (hu)
EP (2) EP2137186B1 (hu)
JP (2) JP5527761B2 (hu)
KR (1) KR101504773B1 (hu)
CN (1) CN101715453B (hu)
AU (1) AU2008231304B2 (hu)
BR (1) BRPI0809141A2 (hu)
CA (1) CA2681136C (hu)
CR (2) CR11053A (hu)
DK (1) DK2137186T3 (hu)
EA (1) EA017389B1 (hu)
ES (1) ES2563458T3 (hu)
HR (1) HRP20160350T1 (hu)
HU (1) HUE028954T2 (hu)
IL (1) IL200867A (hu)
MX (1) MX2009009968A (hu)
NZ (1) NZ579834A (hu)
PL (1) PL2137186T3 (hu)
PT (1) PT2137186E (hu)
RS (1) RS54706B1 (hu)
SI (1) SI2137186T1 (hu)
UA (1) UA98955C2 (hu)
WO (1) WO2008118468A1 (hu)
ZA (1) ZA201308294B (hu)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
CA2680853C (en) * 2007-03-23 2012-07-17 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
NZ579834A (en) * 2007-03-23 2012-03-30 Amgen Inc Heterocyclic compounds as selective inhibitors of PI3K activity
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
ES2587738T3 (es) 2007-12-21 2016-10-26 Ucb Biopharma Sprl Derivados de quinoxalina y quinolina como inhibidores de quinasa
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン, エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
GB0819593D0 (en) 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
GB0821693D0 (en) * 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
US8592415B2 (en) * 2009-02-11 2013-11-26 Reaction Biology Corp. Selective kinase inhibitors
ES2598358T3 (es) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
ES2568508T3 (es) 2009-03-06 2016-04-29 Ucb Biopharma Sprl Derivados de triazina como inhibidores de cinasas
EP2426135A4 (en) 2009-04-27 2013-02-20 Shionogi & Co UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
GB0908957D0 (en) * 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
EP2445900B1 (en) 2009-06-25 2016-03-02 Amgen, Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
AU2010273816B2 (en) 2009-06-29 2015-07-09 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011058111A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Aminopurine derivatives as kinase inhibitors
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
EP2499144B1 (en) 2009-11-12 2013-10-23 UCB Pharma, S.A. Quinoline and quinoxaline derivatives as kinase inhibitors
ES2520345T3 (es) 2009-11-12 2014-11-11 Ucb Pharma, S.A. Derivados de quinolina y quinoxalina en calidad de inhibidores de quinasa
US8957090B2 (en) 2009-11-12 2015-02-17 Ucb Pharma S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
EP2513109A1 (en) * 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011093365A1 (ja) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 含窒素複素環化合物
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2588473A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
AU2011272853A1 (en) * 2010-07-01 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
CA2803259A1 (en) * 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
AU2011272850A1 (en) 2010-07-02 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
AU2011302196B2 (en) * 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
JP2013541591A (ja) * 2010-11-04 2013-11-14 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
JP2013545749A (ja) * 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
US8765768B2 (en) * 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としての複素環化合物
EP2763994A4 (en) * 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
MX368833B (es) * 2013-01-31 2019-10-18 Vertex Pharma Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA036942B1 (ru) 2013-11-11 2021-01-18 Эмджен Инк. Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015171725A1 (en) 2014-05-06 2015-11-12 Amgen Inc. Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer.
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP6291601B2 (ja) 2014-07-04 2018-03-14 ルピン・リミテッド Pi3k阻害剤としてのキノリジノン誘導体
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10626094B2 (en) * 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
EA037663B1 (ru) 2015-01-16 2021-04-28 Те Дженерал Хоспитал Корпорейшн СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
PT3262046T (pt) 2015-02-27 2020-12-24 Incyte Corp Sais de inibidor de pi3k e processos para a sua preparação
CN106008479B (zh) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CA3013490C (en) * 2016-03-05 2021-09-14 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017281797A1 (en) 2016-06-24 2019-01-24 Infinity Pharmaceuticals, Inc. Combination therapies
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN108069899B (zh) * 2016-11-18 2021-01-08 中国科学院大连化学物理研究所 一种制备2,3-取代喹啉类衍生物的方法
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CN114144414A (zh) 2019-05-21 2022-03-04 美国安进公司 固态形式
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN114276326B (zh) * 2021-03-09 2022-11-11 南京征祥医药有限公司 喹啉化合物的盐及制备方法和应用
CN113218936B (zh) * 2021-06-07 2021-09-10 江苏欣诺科催化剂有限公司 锇酸钾的纯度检测方法
WO2023016477A1 (en) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2006114180A1 (de) * 2005-04-25 2006-11-02 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
US20090170848A1 (en) 2006-03-02 2009-07-02 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
WO2007103759A2 (en) 2006-03-02 2007-09-13 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
NZ579834A (en) * 2007-03-23 2012-03-30 Amgen Inc Heterocyclic compounds as selective inhibitors of PI3K activity
CA2700088A1 (en) 2007-09-26 2009-04-02 Astellas Pharma Inc. Quinolone derivative
ES2587738T3 (es) * 2007-12-21 2016-10-26 Ucb Biopharma Sprl Derivados de quinoxalina y quinolina como inhibidores de quinasa
EP2346508B1 (en) * 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
GB0819593D0 (en) * 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
GB0821693D0 (en) * 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
ES2598358T3 (es) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
CA2760791C (en) * 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2445900B1 (en) * 2009-06-25 2016-03-02 Amgen, Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
US8957090B2 (en) 2009-11-12 2015-02-17 Ucb Pharma S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
EP2513109A1 (en) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses

Also Published As

Publication number Publication date
EP2137186A1 (en) 2009-12-30
RS54706B1 (en) 2016-08-31
UA98955C2 (ru) 2012-07-10
IL200867A0 (en) 2010-05-17
JP2014058526A (ja) 2014-04-03
KR20100015795A (ko) 2010-02-12
US20150045361A1 (en) 2015-02-12
AU2008231304A1 (en) 2008-10-02
HRP20160350T1 (hr) 2016-05-06
JP5819382B2 (ja) 2015-11-24
SI2137186T1 (sl) 2016-04-29
EP3045458A1 (en) 2016-07-20
AU2008231304B2 (en) 2011-05-12
CN101715453A (zh) 2010-05-26
DK2137186T3 (en) 2016-04-18
US20180105532A1 (en) 2018-04-19
US20200048265A1 (en) 2020-02-13
KR101504773B1 (ko) 2015-03-20
WO2008118468A1 (en) 2008-10-02
CA2681136A1 (en) 2008-10-02
CN101715453B (zh) 2012-06-27
BRPI0809141A2 (pt) 2014-08-26
CR11053A (es) 2009-10-23
US8901135B2 (en) 2014-12-02
US20120220586A1 (en) 2012-08-30
ZA201308294B (en) 2014-07-30
PL2137186T3 (pl) 2016-09-30
US8586739B2 (en) 2013-11-19
CR11582A (es) 2011-01-10
US20090137581A1 (en) 2009-05-28
IL200867A (en) 2014-11-30
CA2681136C (en) 2012-05-22
US8193199B2 (en) 2012-06-05
JP5527761B2 (ja) 2014-06-25
EP2137186B1 (en) 2016-01-27
PT2137186E (pt) 2016-03-30
JP2010522179A (ja) 2010-07-01
US9873701B2 (en) 2018-01-23
MX2009009968A (es) 2009-10-08
NZ579834A (en) 2012-03-30
EA017389B1 (ru) 2012-12-28
US20120220585A1 (en) 2012-08-30
EA200901276A1 (ru) 2010-04-30
ES2563458T3 (es) 2016-03-15

Similar Documents

Publication Publication Date Title
EP2137186B1 (en) Heterocyclic compounds and their uses
US9873704B2 (en) Heterocyclic compounds and their uses
CA2680783C (en) Heterocyclic compounds and their uses
US8754089B2 (en) Heterocyclic compounds and their uses
US8835432B2 (en) Heterocyclic compounds and their uses